SPONSOR
Sichuan Baili Pharmaceutical Co., Ltd.
Total Trials
12
Recruiting
12
Phases
Phase 1, Phase 2, Phase 3, Phase 3, Phase 2
Conditions studied: Head and Neck Squamous Cell CarcinomasSolid TumorNon-small Cell Lung CancerBreast CancerNon-small Cell Lung Cancer Stage IIIRecurrent GliomaSmall Cell Lung CancerRheumatoid ArthritisNeuroendocrine TumorsGastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd. is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Head and Neck Squamous Cell Carcinomas, Solid Tumor, Non-small Cell Lung Cancer, Breast Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 3, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan Baili Pharmaceutical Co., Ltd.
How many clinical trials has Sichuan Baili Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd., of which 12 are actively recruiting participants. These trials cover conditions including Head and Neck Squamous Cell Carcinomas, Solid Tumor, Non-small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan Baili Pharmaceutical Co., Ltd. research focus on?
Sichuan Baili Pharmaceutical Co., Ltd. clinical trials span Head and Neck Squamous Cell Carcinomas, Solid Tumor, Non-small Cell Lung Cancer, Breast Cancer, Non-small Cell Lung Cancer Stage III, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan Baili Pharmaceutical Co., Ltd. clinical trial?
To participate in a Sichuan Baili Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan Baili Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Sichuan Baili Pharmaceutical Co., Ltd.
NCT06469008 Phase 1
Recruiting
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinomas
NCT07642024 Phase 2, Phase 3
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
Non-small Cell Lung Cancer
NCT06493864 Phase 1
Recruiting
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Breast Cancer
NCT07640789 Phase 3
Recruiting
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Non-small Cell Lung Cancer Stage III
NCT04794972 Phase 1
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Recurrent Glioma
NCT05924841 Phase 2
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer
NCT06838273 Phase 3
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Non-small Cell Lung Cancer
NCT06857227 Phase 1
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
NCT06505824 Phase 1
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Small Cell Lung Cancer
NCT07232407 Phase 1
Recruiting
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Gastrointestinal Tumors
NCT07654400 Phase 2
Recruiting
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
NCT07678970 Phase 1
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Gastrointestinal Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology